skip to content

Roche Venture Fund Portfolio

Our current portfolio includes more than 30 companies. We seek to add value to our companies and create highly valuable business enterprises.

Aligos

We discover targeted antiviral therapies for chronic hepatitis B (CHB), COVID-19, and optimized therapeutics for Nonalcoholic Steatohepatitis (NASH).

Blueprint Medicines

Every day, we seek to transform science into more time for life. Time to be with families, time to be productive community members, time to feel the small moments of joy that shape our lives.

Bonum Therapeutics

Bonum Therapeutics is focused on a proven technology that utilizes allosteric regulation to create targeted, highly active, and less toxic medicines.

Civi Biopharma

Focused on creating novel therapies against diseases where the unmet medical need exists.

Cour

COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated disease.

DiogenX

DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of diabetic patients around the world.

Enliven Therapeutics

We are a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors to help patients with cancer live longer and better.

Enthera

First-in-class therapeutics for auto-immune disorders

Entrada

Overcoming the challenge of intracellular target access to transform the treatment of devastating diseases

Fabric Genomics

Fabric Genomics is AI-driven genomics software to accurately analyze whole genomes, exomes & gene panels clinically actionable insights

Forcefield Therapeutics

Revolutionising the treatment of heart attacks.

Freenome

Freenome is a biotechnology company based in South San Francisco that has pioneered the most comprehensive multiomics platform for early cancer detection with a simple blood test.

Glycoera

GlycoEra has developed a game-changing protein engineering and production platform to build a high-value pipeline of medicines.

Kumquat Biosciences

Developing innovative therapies to bring about sustainable and life-changing benefits to cancer patients.

Lumos Pharma

Lumos Pharma is a clinical stage, biopharmaceutical company developing therapeutics for rare diseases.

Minoryx

Minoryx is focused on the discovery and development of novel treatments for severe, orphan diseases of the central nervous system with high unmet medical need.

Mironid

Mironid® is developing novel small-molecule therapeutics that directly target the central signalling mechanism that drives ADPKD.

Mission Therapeutics

Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas

Nimble Therapeutics

A biotechnology company inspired by Nature’s elegance and turbocharged by a paradigm-shifting peptide discovery & development engine.

NMD Pharma

NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases.

Noema Pharma

Developing therapies to help both orphan and larger patient populations with conditions of the brain and nervous system live their lives to the fullest.

River 3 Renal

River Renal Companies were founded by Bain Capital Life Sciences in partnership with Narrow River Management in 2020.

Sarepta Therapeutics

We are focused on the development of precision genetic medicines to treat rare neuromuscular and central nervous system diseases

Syapse

Dedicated to extinguishing the fear and burden of serious disease by advancing real-world care.

Tango Therapeutics

We are leveraging the principle of synthetic lethality to develop medicines that take direct aim at specific tumors.

Tempest Therapeutics

Tempest Therapeutics is developing first-in-class small molecule product candidates with broad potential benefit to patients.

Vivet Therapeutics

Vivet Therapeutics is a clinical-stage emerging biotechnology company developing novel gene therapy treatments for rare, inherited metabolic diseases.

  • Afferent (acquired by Merck)

  • Alios (acquired by Johnson+Johnson)

  • Ambit (acquired by Daiichi Sankyo)

  • Ambrx (acquired by Wuxi)

  • Artus (acquired by Qiagen)

  • Avexis (acquired by Novartis)

  • BioFire (acquired by bioMérieux)

  • BioXell (acquired by Cosmo)

  • Care Innovations (acquired by PRA Health Sciences)

  • CGI (acquired by Gilead)

  • DVS (acquired by Fluidigm)

  • Envoy (acquired by Takeda)

  • Flatiron (acquired by Roche)

  • Foundation Medicine (acquired by Roche)

  • Good Therapeutics (acquired by Roche)

  • HistoRx (acquired by Genoptix)

  • Leukosite (acquired by Millennium)

  • Lino Biotech (acquired by Miltenyi Biotech)

  • LTI (acquired by Bial)

  • Maculogix (acquired by LumiThera)

  • Memory (acquired by Roche)

  • Miikana (acquired by EntreMed)

  • MySugr (acquired by Roche)

  • Pandion (acquired by Merck)

  • Purigen (acquired by Bionano)

  • Second Genome (acquired by Genevive)

  • Sequana (acquired by Celera)

  • Stratos Genomics (acquired by Roche)

  • Syrrx (acquired by Takeda)

  • Tripath (acquired by Becton Dickinson)

  • Viewics (acquired by Roche)

  • Zikanii (acquired by Eloxx)

  • 23andMe

  • Addex

  • Aileron

  • Allakos

  • Anadys

  • Black Diamond Therapeutics

  • C4 Therapeutics

  • Caliper

  • Centessa

  • Complete Genomics

  • Conatus

  • Corvus Pharmaceuticals

  • Curetis

  • CV Therapeutics

  • CytomX

  • deCode

  • Fibrogen, Inc

  • Halozyme Therapeutics

  • Horizon Discovery

  • IDEAYA Biosciences

  • Jasper Therapeutics

  • Miragen

  • Pharmasset

  • Protein Design Labs, Inc

  • Senseonics

  • Taimed

  • TiGenix

  • Vaxcyte

  • Xenon

Discover more

Roche Venture FundRoche Venture Fund

We are the corporate venture fund of Roche, a global leader in bringing medicines and in vitro diagnostics to the benefit of patients.

Roche Venture Fund News ArchiveRoche Venture Fund